These findings underscore the therapeutic potential of the Hesp + BL combination as a promising strategy for lung cancer treatment, meriting further exploration in diverse lung cancer cell lines to validate and expand its applicability in developing novel therapeutic approaches. Here, TMPRSS11A is linked to lung carcinoma.